SOUTHLAKE, Texas, April 24, 2025 /PRNewswire/ -- Renibus Therapeutics ® ("Renibus"), a clinical late-stage biopharmaceutical company focusing on the prevention and treatment of cardiac, renal, and ...
Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果